Reviewing Immunomedics Inc. (IMMU)’s and Trevi Therapeutics Inc. (NASDAQ:TRVI)’s results

Immunomedics Inc. (NASDAQ:IMMU) and Trevi Therapeutics Inc. (NASDAQ:TRVI), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immunomedics Inc. 17 0.00 155.05M -1.62 0.00
Trevi Therapeutics Inc. 4 0.00 1.95M -1.72 0.00

Table 1 highlights Immunomedics Inc. and Trevi Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 provides us Immunomedics Inc. and Trevi Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immunomedics Inc. 902,502,910.36% -121.3% -63.3%
Trevi Therapeutics Inc. 53,179,884.37% 0% 0%

Analyst Ratings

The table shown features the ratings and recommendations for Immunomedics Inc. and Trevi Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Immunomedics Inc. 0 1 2 2.67
Trevi Therapeutics Inc. 0 0 0 0.00

$24.67 is Immunomedics Inc.’s average price target while its potential upside is 40.57%.

Institutional & Insider Ownership

Institutional investors owned 95.3% of Immunomedics Inc. shares and 47.6% of Trevi Therapeutics Inc. shares. Insiders owned 7.19% of Immunomedics Inc. shares. Insiders Comparatively, owned 13.9% of Trevi Therapeutics Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Immunomedics Inc. -2.06% 4.98% -1.34% -1.4% -34.91% 3.36%
Trevi Therapeutics Inc. -0.66% -17.1% 0% 0% 0% -23.83%

For the past year Immunomedics Inc. had bullish trend while Trevi Therapeutics Inc. had bearish trend.


On 8 of the 10 factors Immunomedics Inc. beats Trevi Therapeutics Inc.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.